Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is to see if combining gemcitabine with bevacizumab works in treating
patients who have advanced pancreatic cancer. Drugs used in chemotherapy work in different
ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies,
such as bevacizumab, can block cancer growth in different ways. Some block the ability of
cancer cells to grow and spread. Others find cancer cells and help kill them or deliver
cancer-killing substances to them. Combining chemotherapy with a monoclonal antibody may kill
more tumor cells